These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

768 related articles for article (PubMed ID: 19218475)

  • 1. Calcineurin inhibitor nephrotoxicity.
    Naesens M; Kuypers DR; Sarwal M
    Clin J Am Soc Nephrol; 2009 Feb; 4(2):481-508. PubMed ID: 19218475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcineurin inhibitor-induced renal allograft nephrotoxicity.
    Krejci K; Tichy T; Bachleda P; Zadrazil J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2010 Dec; 154(4):297-306. PubMed ID: 21293540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity.
    Bentata Y
    Artif Organs; 2020 Feb; 44(2):140-152. PubMed ID: 31386765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras.
    Nankivell BJ; PʼNg CH; OʼConnell PJ; Chapman JR
    Transplantation; 2016 Aug; 100(8):1723-31. PubMed ID: 27306529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arteriosclerosis in zero-time biopsy is a risk factor for tacrolimus-induced chronic nephrotoxicity.
    Yagisawa T; Omoto K; Shimizu T; Ishida H; Tanabe K
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():51-7. PubMed ID: 26031587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium.
    Jacobson PA; Schladt D; Israni A; Oetting WS; Lin YC; Leduc R; Guan W; Lamba V; Matas AJ;
    Transplantation; 2012 Mar; 93(6):624-31. PubMed ID: 22334041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcineurin Inhibitors Nephrotoxicity Prevention Strategies With Stress on Belatacept-Based Rescue Immunotherapy: A Review of the Current Evidence.
    El Hennawy HM; Faifi ASA; El Nazer W; Mahedy A; Kamal A; Al Faifi IS; Abdulmalik H; Safar O; Zaitoun MF; Fahmy AE
    Transplant Proc; 2021 Jun; 53(5):1532-1540. PubMed ID: 34020797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies.
    Olyaei AJ; de Mattos AM; Bennett WM
    Curr Opin Crit Care; 2001 Dec; 7(6):384-9. PubMed ID: 11805539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future.
    de Mattos AM; Olyaei AJ; Bennett WM
    Am J Kidney Dis; 2000 Feb; 35(2):333-46. PubMed ID: 10676738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CARI guidelines. Calcineurin inhibitors in renal transplantation: nephrotoxicity and calcineurin inhibitors.
    Coates PT;
    Nephrology (Carlton); 2007 Feb; 12 Suppl 1():S85-7. PubMed ID: 17316286
    [No Abstract]   [Full Text] [Related]  

  • 13. [Calcineurin inhibitor nephrotoxicity in renal allografts].
    Takeda A; Morozumi K
    Nihon Jinzo Gakkai Shi; 2011; 53(4):610-4. PubMed ID: 21688481
    [No Abstract]   [Full Text] [Related]  

  • 14. Calcineurin Inhibitor-Sparing Strategies in Renal Transplantation: Where Are We? A Comprehensive Review of the Current Evidence.
    Camilleri B; Bridson JM; Halawa A
    Exp Clin Transplant; 2016 Oct; 14(5):471-483. PubMed ID: 27213490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcineurin inhibitor-induced nephrotoxicity and renal expression of P-glycoprotein.
    Joy MS; Nickeleit V; Hogan SL; Thompson BD; Finn WF
    Pharmacotherapy; 2005 Jun; 25(6):779-89. PubMed ID: 15927895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity.
    Metalidis C; Lerut E; Naesens M; Kuypers DR
    Transplantation; 2011 May; 91(10):1098-102. PubMed ID: 21544031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy.
    Weir MR; Ward MT; Blahut SA; Klassen DK; Cangro CB; Bartlett ST; Fink JC
    Kidney Int; 2001 Apr; 59(4):1567-73. PubMed ID: 11260422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity.
    Khanna A; Plummer M; Bromberek C; Bresnahan B; Hariharan S
    Kidney Int; 2002 Dec; 62(6):2257-63. PubMed ID: 12427154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcineurin inhibitor-associated early renal insufficiency in cardiac transplant recipients: risk factors and strategies for prevention and treatment.
    Baran DA; Galin ID; Gass AL
    Am J Cardiovasc Drugs; 2004; 4(1):21-9. PubMed ID: 14967063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacrolimus and cyclosporine nephrotoxicity in native kidneys of pancreas transplant recipients.
    Fioretto P; Najafian B; Sutherland DE; Mauer M
    Clin J Am Soc Nephrol; 2011 Jan; 6(1):101-6. PubMed ID: 21051744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.